15 results about "Glycated hemoglobin" patented technology

This invention provides a hypoglycemic subspecies of Bifidobacterium animalis (Liver) and its applications. The Bifidobacterium animalis (Liver) subspecies is named Tianshan-1 and is deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 35821 on September 5, 2025. Cell experiments show that Tianshan-1 significantly promotes the secretion of GLP-1 from human colorectal adenocarcinoma cells NCI-H716 and upregulates GCG gene expression levels. Animal experiments confirm that this strain significantly increases serum GLP-1 concentration in diabetic mice and reduces fasting blood glucose and glycated hemoglobin levels, with no significant difference in hypoglycemic effect compared to the positive control. This strain is a food-grade safe probiotic with a clear mechanism of action and stable effects, providing a safe, long-lasting, and industrially viable new probiotic resource for diabetes prevention and treatment, with broad application prospects.

The invention discloses a diabetes mellitus personalized nursing intelligent medical management system based on an AI algorithm, and belongs to the crossing field of intelligent medical treatment and artificial intelligence. According to the system, a three-layer dynamic coupling architecture of data perception, AI decision making and interactive execution is adopted, algorithms such as a space-time diagram convolutional network, hierarchical reinforcement learning and differential privacy federated learning are fused, and multi-source data intelligent fusion, 72-hour complication prospective early warning, minute-level personalized nursing scheme generation and model adaptive evolution are achieved. Clinical verification shows that the system can remarkably reduce the glycosylated hemoglobin level of a patient, improve the blood glucose standard-reaching rate and the scheme execution rate, reduce diabetes related emergency treatment and relieve the workload of medical care, and is low in deployment cost, convenient to operate, high in privacy, suitable for management of various diabetes mellitus and capable of being expanded to other chronic diseases, such as diabetes mellitus, diabetes mellitus, diabetes mellitus and diabetes mellitus. The system is suitable for multiple scenes such as medical institutions, communities and families.

The glycosylated hemoglobin quantitative detection and analysis device comprises a machine body, a detection area and a display control area are preset on the left side and the right side of the machine body, a stand column is installed in the detection area, the stand column is sleeved with a lower ring plate, and the stand column over the lower ring plate is sleeved with an upper ring plate; a plurality of mutually aligned placing holes are formed in the upper ring plate and the lower ring plate, a concave cavity in the radial direction is formed in the part, between the upper ring plate and the lower ring plate, of the stand column, a second movable plate and a first movable plate are installed on the concave cavity and the side face opposite to the concave cavity respectively, and bayonets aligned with the placing holes are formed in the second movable plate and the first movable plate; and an excitation light source and a photoelectric detector which are opposite to each other are respectively arranged in the movable plate II and the movable plate I. A sample is placed in the placing holes of the upper ring plate and the lower ring plate, during detection, the first movable plate and the second movable plate actively approach and surround the sample, a good internal light shielding environment is obtained, and external light is difficult to enter the interior to affect a detection result.

The invention relates to lactobacillus paracasei KXW5 with a hypoglycemic function and application thereof, and belongs to the technical field of microorganisms. In order to excavate a microecological preparation for treating hyperglycemia-related diseases, a strain of lactobacillus paracasei KXW5 is separated, and in-vivo and in-vitro experiments prove that the strain has remarkable blood sugar reducing capacity, including promoting proliferation of high-glucose-induced INS-1 cells, improving the relative expression quantity of MafA genes in the high-glucose-induced INS-1 cells and improving the blood sugar reducing capacity. The fasting blood glucose level, postprandial blood glucose level, insulin resistance level, glycosylated hemoglobin level, liver copper ion level and the expression level of copper death related genes FDX1 and DLAT in the liver of the type II diabetes mellitus patient are reduced, and the oral glucose tolerance of the type II diabetes mellitus patient is enhanced. The strain KXW5 provided by the invention can be used for preparing medicines for reducing blood sugar and preventing and / or treating diabetes mellitus or health-care foods for assisting in reducing blood sugar, and opens up a new way for preventing and treating diabetes mellitus.

Aspects of the present disclosure include methods for treating a subject having a metabolic disorder by neuromodulation. Methods according to certain embodiments include applying electrical stimulation to the spinal cord of a subject (e.g., a subject diagnosed as having or determined to have diabetes or prediabetes) in a manner sufficient to treat at least one symptom of the metabolic disorder in the subject. In some embodiments, neuromodulation is sufficient to treat one or more symptoms of diabetes or prediabetes such as fasting plasma glucose concentration, non-fasting plasma glucose concentration, elevated hbA1c, glucose tolerance and insulin secretion by the subject. Systems having one or more electrodes configured for applying electrical stimulation to the spinal cord of the subject suitable for practicing the subject methods are also described.

The invention relates to a method and system for predicting the anxiety mood prevalence rate of a diabetic child patient, and belongs to the field of artificial intelligence prediction. According to the method, multi-dimensional clinical data such as demographic data, treatment modes, management behaviors and metabolic indexes of diabetic children are collected, evaluation results of a children anxiety mood disorder screening table (SCARED) are combined, single-factor analysis, correlation analysis and multi-factor Logistic regression analysis are carried out, and an anxiety mood prediction model is constructed. The model takes age, an insulin treatment mode and glycosylated hemoglobin as core variables, and can accurately predict the anxiety risk of a child patient. The system comprises a data acquisition module, a psychological assessment module, an analysis modeling module, a risk prediction module and a report generation module, and realizes automatic data integration, model construction and individual intervention suggestion output. Clinical verification shows that the model prediction efficiency is excellent, and the method has good clinical application value and is beneficial to early recognition and intervention of anxiety mood of diabetic children and improvement of physical and psychological health and disease management quality of the diabetic children.

A method of data analysis is provided. The method is used for finding a long-term trend of blood glucose concentration. The method builds a model for estimating long-term glycemic variability and long-term blood glucose trajectory. Based on single-erythrocyte-level glycated hemoglobin distribution, the glycemic variability is analyzed. A first analysis method is to give a number. The number shows the level of the historical glycemic variabilities. A second analysis method is to restore the blood glucose trajectory over the past 20 weeks. Based on the single-erythrocyte-level glycated hemoglobin distribution, the present invention easily assesses blood-glucose-related clinical information for about 150 days. Hence, an important complement is obtained for diabetes-related or glucose-monitoring-related clinical applications.

The invention relates to lactobacillus rhamnosus KXW1 with a hypoglycemic function and application of the lactobacillus rhamnosus KXW1, and belongs to the technical field of microorganisms. In order to excavate a microecological preparation for treating hyperglycemia-related diseases, a strain of lactobacillus rhamnosus KXW1 is separated, and in-vivo and in-vitro experiments prove that the strain has remarkable blood sugar reducing capacity, including promoting proliferation of high-glucose-induced INS-1 cells and increasing the relative expression quantity of MafA genes in the high-glucose-induced INS-1 cells, so that the hyperglycemia-related diseases can be treated. The fasting blood glucose level, postprandial blood glucose level, insulin resistance level, glycosylated hemoglobin level, liver copper ion level and the expression level of copper death related genes FDX1 and DLAT in the liver of the type II diabetes mellitus patient are reduced, and the oral glucose tolerance of the type II diabetes mellitus patient is enhanced. The strain KXW1 provided by the invention can be used for preparing medicines for reducing blood sugar and preventing and / or treating diabetes mellitus or health-care foods for assisting in reducing blood sugar, and opens up a new way for preventing and treating diabetes mellitus.

Disclosed herein are methods of treating diabetic cardiomyopathy (DbCM) using an aldose reductase inhibitor, and methods of inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM using an aldose reductase inhibitor. Also disclosed are aldose reductase inhibitors and compositions thereof for use in treating diabetic cardiomyopathy (DbCM), or inhibiting decline in cardiac functional capacity and / or progression to overt heart failure in a subject with DbCM. Subjects treated by the methods and uses are not administered a sodium-glucose cotransporter-2 (SGLT2) inhibitor and / or have an HbA1C value greater than 8.5%.

A wearable device for determining glycated hemoglobin level, includes at least three radiation sources; at least two radiation detectors configured to detect photoplethysmographic (PPG) signals of the at least three different wavelengths backscattered by the biological tissues; and a processor configured to: activate the radiation sources and the radiation detectors in pairs of measurement channels for the PPG signals; sequentially detect the PPG signals through each of the measurement channels; form, from the detected PPG signals, a dataset representing a time series of absorption of the PPG signals by the biological tissues of the user; generate a pre-processed dataset by carrying out a pre-processing of the dataset; and determine a glycated hemoglobin level based on the pre-processed dataset by a pre-trained machine learning model.

Provided is the use of a compound or a pharmaceutically acceptable salt thereof in the treatment of glucose metabolic diseases. The compound or pharmaceutically acceptable salt thereof can significantly lower the blood glucose level and improve the metabolic phenotype of diseases associated with the glucose metabolism, and can specifically reduce the food intake of mice and improve their blood glucose and glycated hemoglobin levels, glucose tolerance, and insulin sensitivity.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

The present invention pertains to the field of medical technology, specifically disclosing the pharmaceutical application of dimyricetin-based diselenide in type II diabetes. After four weeks of continuous administration, compared with the model control group, the test substances DMS-ASD and AQ-C-a demonstrated effects that were basically equivalent to the positive control drug, semaglutide injection, in reducing fasting blood glucose levels after 16 hours of fasting in db / db mice, reducing random blood glucose levels in db / db mice, inhibiting postprandial blood glucose elevations in db / db mice, decreasing the HbA1c content of glycated hemoglobin in db / db mice, and influencing body weight and food intake in db / db mice. The pharmaceutical application of dimyricetin-based diselenide in type II diabetes holds great promise.

A wearable device for determining glycated hemoglobin level, includes at least three radiation sources; at least two radiation detectors configured to detect photoplethysmographic (PPG) signals of the at least three different wavelengths backscattered by the biological tissues; and a processor configured to: activate the radiation sources and the radiation detectors in pairs of measurement channels for the PPG signals; sequentially detect the PPG signals through each of the measurement channels; form, from the detected PPG signals, a dataset representing a time series of absorption of the PPG signals by the biological tissues of the user; generate a pre-processed dataset by carrying out a pre-processing of the dataset; and determine a glycated hemoglobin level based on the pre-processed dataset by a pre-trained machine learning model.

A method of providing personalized treatment for a diabetes patient including a remote device which is configured to receive a first data indicative of an analyte level of a subject during a first time period, retrieve a first glycated hemoglobin level for the subject associated with the first time period, calculate a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level, compare the calculated first personal apparent glycation ratio to a representative apparent glycation ratio, generate a recommendation based on the comparison, and display a graphical interface comprising the calculated first personal apparent glycation ratio, the representative apparent glycation ratio, and the comparison.